{"id":95847,"date":"2015-03-12T09:17:17","date_gmt":"2015-03-12T08:17:17","guid":{"rendered":"https:\/\/clinical.r-biopharm.com\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/"},"modified":"2018-12-17T12:31:49","modified_gmt":"2018-12-17T11:31:49","slug":"monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra","status":"publish","type":"post","link":"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/","title":{"rendered":"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column][vc_column_text css=&#8221;.vc_custom_1540896797829{margin-bottom: 0px !important;}&#8221;]<strong>Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari\u00a0RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per\u00a0infliximab.<\/strong><\/p>\n<p><!--more--><\/p>\n<p>I ricercatori hanno dimostrato che\u00a0tale metodo analitico\u00a0mostra la stessa\u00a0reattivit\u00e0 di\u00a0Remicade\u00ae anche verso RemsimaTM ed Inflectra\u00ae\u00a0 ed \u00e8 pertanto adatto per il monitoraggio terapeutico (TDM) dei biosimilari.<\/p>\n<p>Il metodo validato clinicamente \u00e8 stato\u00a0convertito\u00a0nel test ELISA <a title=\"View RIDASCREEN IFX Monitoring for the quantitative determination of infliximab\" href=\"http:\/\/www.r-biopharm.com\/products\/clinical-diagnostics\/gastroenterology-test\/inflammatory-bowel-diseases\/item\/ridascreen-ifx-monitoring\">RIDASCREEN IFX Monitoring<\/a> marcato CE di R\u2013Biopharm. Per ulteriori informazioni, si prega di leggere l\u2019<a href=\"https:\/\/www.ecco-ibd.eu\/index.php\/publications\/congress-abstract-s\/abstracts-2015\/item\/p040-the-biosimilars-of-infliximab-are-equally-well-quantified-in-a-clinically-validated-infliximab-assay.html\">abstract<\/a>.<\/p>\n<h3>Importanza del monitoraggio terapeutico farmacologico<\/h3>\n<p>Il monitoraggio terapeutico farmacologico\u00a0 (TDM) \u00e8 uno strumento attraverso il quale \u00e8 possibile monitorare le concentrazioni del farmaco nel sangue di un paziente. In molti casi, il TDM \u00e8 cruciale per il successo del trattamento\u00a0dal momento che la\u00a0biodisponibilit\u00e0 \u00e8\u00a0di estrema rilevanza\u00a0per il buon funzionamento del farmaco. I livelli del farmaco variano in base\u00a0alle singole\u00a0farmacocinetiche. Il TDM consente di ottimizzare il trattamento dei pazienti regolando la dose al livello richiesto singolarmente ed\u00a0inoltre aiuta a ridurre i costi del trattamento.<\/p>\n<p>Per maggiori informazioni sull\u2019importanza del TDM, si prega di leggere il <a title=\"View the study publication: Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S001650851500253X\" target=\"_blank\" rel=\"noopener\">TAXIT study<\/a>.<\/p>\n<h3>Informazioni su\u00a0Infliximab &amp; Biosimilari<\/h3>\n<p>Infliximab (IFX) \u00e8 un anticorpo chimerico diretto contro la citochina pro\u2013infiammatoria TNFa, un cosiddetto TNF\u03b1\u2013bloccante. Esso viene utilizzato per un certo numero di malattie infiammatorie come la colite ulcerosa e il morbo di Crohn.<\/p>\n<p>Il farmaco\u00a0Remicade\u00ae era protetto da brevetto fino al 2014. I biosimilari RemsimaTMed Inflectra\u00ae sono stati approvati dall\u2019 Ageniza Europea di Medicina\u00a0(EMA).[\/vc_column_text][vc_cta h2=&#8221;Hai domande?&#8221; shape=&#8221;square&#8221; style=&#8221;flat&#8221; add_button=&#8221;right&#8221; btn_title=&#8221;Contattaci&#8221; btn_style=&#8221;flat&#8221; btn_shape=&#8221;square&#8221; btn_color=&#8221;inverse&#8221; btn_link=&#8221;url:mailto%3Aifx%40r-biopharm.de|&#8221;]Vuoi ricevere maggiori informazioni? ContattaR-Biopharm Italia.[\/vc_cta][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=&#8221;.vc_custom_1540896797829{margin-bottom: 0px !important;}&#8221;]Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari\u00a0RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per\u00a0infliximab.<\/p>\n","protected":false},"author":27,"featured_media":95849,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[476,478,479],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8<\/title>\n<meta name=\"description\" content=\"Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per infliximab.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"og:description\" content=\"Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per infliximab.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/\" \/>\n<meta property=\"og:site_name\" content=\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-12T08:17:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-12-17T11:31:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/devclinical.r-biopharm.com\/wp-content\/uploads\/2015\/03\/2015-03_Medikamentenflaeschchen-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"252\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Janine Dege\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Janine Dege\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/\",\"url\":\"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/\",\"name\":\"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"isPartOf\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\"},\"datePublished\":\"2015-03-12T08:17:17+00:00\",\"dateModified\":\"2018-12-17T11:31:49+00:00\",\"author\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f\"},\"description\":\"Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per infliximab.\",\"breadcrumb\":{\"@id\":\"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/devclinical.r-biopharm.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\",\"url\":\"https:\/\/devdevclinical.r-biopharm.com\/\",\"name\":\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f\",\"name\":\"Janine Dege\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bb89e83feb98f248810cb1fb31dc223f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bb89e83feb98f248810cb1fb31dc223f?s=96&d=mm&r=g\",\"caption\":\"Janine Dege\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","description":"Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per infliximab.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"it_IT","og_type":"article","og_title":"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","og_description":"Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per infliximab.","og_url":"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/","og_site_name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","article_published_time":"2015-03-12T08:17:17+00:00","article_modified_time":"2018-12-17T11:31:49+00:00","og_image":[{"width":690,"height":252,"url":"https:\/\/devclinical.r-biopharm.com\/wp-content\/uploads\/2015\/03\/2015-03_Medikamentenflaeschchen-2.jpg","type":"image\/jpeg"}],"author":"Janine Dege","twitter_misc":{"Written by":"Janine Dege","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/","url":"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/","name":"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","isPartOf":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#website"},"datePublished":"2015-03-12T08:17:17+00:00","dateModified":"2018-12-17T11:31:49+00:00","author":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f"},"description":"Ann Gils ed i suoi colleghi di KU Leuven hanno valutato se i biosimilari RemsimaTM ed Inflectra\u00ae erano altrettanto ben quantificati come Remicade\u00ae (Infliximab, IFX), nella loro sistema analitico clinicamente validato per infliximab.","breadcrumb":{"@id":"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/devclinical.r-biopharm.com\/it\/news\/monitoraggio-farmacologico-dei-biosimilari-di-infliximab-remsimatm-ed-inflectra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/devclinical.r-biopharm.com\/it\/"},{"@type":"ListItem","position":2,"name":"Monitoraggio farmacologico dei Biosimilari di Infliximab, RemsimaTM ed Inflectra\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/devdevclinical.r-biopharm.com\/#website","url":"https:\/\/devdevclinical.r-biopharm.com\/","name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/7bcf9ead36ba80c48ad551e786874e6f","name":"Janine Dege","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bb89e83feb98f248810cb1fb31dc223f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bb89e83feb98f248810cb1fb31dc223f?s=96&d=mm&r=g","caption":"Janine Dege"}}]}},"_links":{"self":[{"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/posts\/95847"}],"collection":[{"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/comments?post=95847"}],"version-history":[{"count":1,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/posts\/95847\/revisions"}],"predecessor-version":[{"id":95848,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/posts\/95847\/revisions\/95848"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/media\/95849"}],"wp:attachment":[{"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/media?parent=95847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/categories?post=95847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/it\/wp-json\/wp\/v2\/tags?post=95847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}